Citi says Friday’s selloff in shares of Apogee Therapeutics (APGE) following Sanofi’s (SNY) Phase 3 amlitelimab data is an overreaction. The firm is a buyer of the stock on the pullback. Citi believes the readout is not negative for the company’s APG279, a fixed dose combination targeting both IL-13 and OX40L. Sanofi’s readout confirms that OX40L monotherapy is not positioned to threaten Apogee’s zumilokibart, the analyst tells investors in a research note. Citi keeps a Buy rating on Apogee with a $95 price target. The stock closed Friday down 12% to $70.02.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics falls -13.0%
- Mizuho biotech analysts hold an analyst/industry conference call
- Apogee Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
- Wayfair upgraded, Instacart initiated: Wall Street’s top analyst calls
- Apogee Therapeutics price target raised to $116 from $109 at Craig-Hallum